Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of STN1012600 alone or with timolol in open-angle glaucoma or ocular hypertension
jRCT2031220266Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sepetaprost in open-angle glaucoma (OAG), normal tension glaucoma (NTG) and ocular hypertension (3 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Adverse events, Change from baseline in mean diurnal intraocular pressure and 1 more. Started Aug 2022; status: completed.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)normal tension glaucoma (NTG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031220266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220266.